Erlotinib Unknown Status Phase 3 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02001896Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
NCT00637910Tarceva Italian Lung Optimization tRial